Clinical trials: End-stage Kidney Disease
Chronic Renal Failure
A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
This is a study to investigate the efficacy and safety of OPC-41061 by 24-week oral administration of OPC-41061 at 15-mg or 30-mg or placebo in patients with chronic renal failure who are undergoing hemodialysis or…
- Trial name
- NCT02331680
- Testing
- OPC-41061
- Where
- 4 sites in Japan
- Volunteers
- 124 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis)
Blood Pressure Lowering in Dialysis (BOLD) Trial
Blood pressure may be one of the most important modifiable risk factors for cardiovascular disease in patients with end-stage-renal-disease undergoing maintenance hemodialysis.
- Conditions
- Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis), Chronic Kidney Diseases, Chronic Kidney Disease Stage 5
- Trial name
- BOLD (NCT03459807)
- Testing
- Anti-Hypertensive medications, Dry Weight Adjustment
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Infective Endocarditis, End Stage Renal Disease
Incidence of Infective Endocarditis in End Stage Renal Disease Patients on Hemodialysis by Transesophageal Echocardiography in Assuit University Hospital
1. To detect in more detail the incidence of infective endocarditis in patients with end stage renal disease (ESRD) on hemodialysis. 2.
- Trial name
- NCT05692089
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Assiut University
End Stage Renal Disease, Peritoneal Dialysis
Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis Patients
The ESCAPE-PD (Effects of add-on SpironolaCtone to losartan versus Alone on Peritoneal mEmbrane among continuous ambulatory Peritoneal Dialysis patients) study is a randomized, open-label, single center, active-controlled…
- Trial name
- ESCAPE-PD (NCT03953950)
- Testing
- Spironolactone, Losartan
- Where
- Thailand
- Volunteers
- 84 people
- Sponsor
- Chiang Mai University
Renal Impairment
Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment
The purpose of this study is to see how the body processes and gets rid of NVA237 in people who have impaired kidney function compared to people whose kidney function is normal.
- Trial name
- NCT01613690
- Testing
- NVA237
- Where
- Russia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
End Stage Renal Failure, Hemodialysis
Catheters Dysfunction Rate After Instillation of Ethanol 60% Lock Solution in Tunneled Silicone Catheter of Chronic Hemodialysis Patients
The primary objective of the study is to examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure…
- Trial name
- Ethanol (NCT00563342)
- Testing
- Ethanol
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Clermont-Ferrand
End Stage Kidney Disease (ESRD)
STARgraft (10401) Pilot
This study is a single site, prospective, single arm evaluation of the safety and effectiveness of the Healionics STARgraft (10401) hemodialysis access graft.
- Trial name
- NCT07555717
- Testing
- STARgraft (10401)
- Where
- Paraguay
- Volunteers
- 20 people
- Sponsor
- Healionics Corporation
Chronic Kidney Disease, End-stage Renal Disease (ESRD)
Effect of Intradialytic Eating Timing on Hemodynamic Stability and Dialysis Adequacy in Hemodialysis Patients
This study aims to examine how different meal timing during hemodialysis affects blood pressure stability and dialysis effectiveness in patients with chronic kidney disease.
- Conditions
- Chronic Kidney Disease, End-stage Renal Disease (ESRD), Hemodialysis
- Trial name
- IDE-HD (NCT07464418)
- Testing
- Intradialytic Eating Timing Intervention
- Where
- Indonesia
- Volunteers
- 40 people
- Sponsor
- Universitas Muhammadiyah Surakarta
Acute Kidney Injury, Chronic Kidney Disease, Stage 3
The Association Between the Duration of Acute Kidney Injury and New-onset Chronic Kidney Disease After Cardiac or Thoracic Aortic Surgery
The investigators aimed to evaluate the association between the duration and stage of acute kidney injury (AKI) and the development of chronic kidney disease during postoperative three years in patients undergoing cardiac or…
- Conditions
- Acute Kidney Injury, Chronic Kidney Disease, Stage 3, Chronic Kidney Disease, Stage 5, Cardiac Surgery
- Trial name
- NCT04172103
- Where
- South Korea
- Volunteers
- 2,009 people
- Sponsor
- Seoul National University Hospital
End Stage Kidney Disease
The Effects of Laughter Therapy on Hemodialysis on Depression
End stage kidney disease is associated with increased depression. Laughter is associated with improvement in depression in chronic disease.
- Trial name
- LOL-HD (NCT04098627)
- Testing
- Laughter Therapy
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Satellite Healthcare
Calciphylaxis
Anti-Interleukin-6 (IL6) in Calciphylaxis
Calciphylaxis is a rare but incredibly dangerous condition that causes small blood vessels in the skin to become blocked by calcium buildup and blood clots. This leads to painful skin sores (necrosis) that do not heal easily.
- Trial name
- NCT07708038
- Testing
- Tocilizumab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Boston Medical Center
End Stage Renal Disease
Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis
OBJECTIVES: I. Evaluate whether hemodialysis providing a 2-pool, variable volume urea kinetic modelling value of 1.05 versus 1.45 reduces mortality and morbidity in patients with end stage renal disease. II.
- Trial name
- HEMO (NCT00004285)
- Testing
- Standard dose, low flux hemodialysis, Standard dose, high flux hemodialysis, High dose, low flux hemodialysis
- Where
- United States
- Volunteers
- 1,846 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Renal Failure
Dose-finding of Rivaroxaban in Hemodialysis
Rivaroxaban is a recently developed factor Xa (FXa) inhibitor for the prevention and treatment of thromboembolic disease. There are no data on dose adjustments in patients with severe chronic renal failure.
- Trial name
- NCT02047006
- Testing
- Rivaroxaban 10 mg
- Where
- 2 sites in Belgium
- Volunteers
- 18 people
- Sponsor
- AZ Sint-Jan AV
Renal Impairment, Renal Disease
Study to Assess Adverse Events and the Movement of Oral Venetoclax Tablet Through the Body of Female Participants Aged 18-75 Years With Impaired Renal Function
Renal insufficiency is common in participants with blood cancers. The main objective of this study is to evaluate adverse events and movement of oral venetoclax tablets through the body of female participants with severe normal…
- Trial name
- NCT04810598
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AbbVie
Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4
Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis Chronic Kidney Disease (CKD) Patients
Aims: The investigators' primary objective is to assess both perceived and actual disease knowledge in local pre-dialysis Chronic Kidney Disease (CKD) patients.
- Conditions
- Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4, Chronic Kidney Disease Stage 5
- Trial name
- NCT01509716
- Where
- Singapore
- Volunteers
- 400 people
- Sponsor
- National University of Singapore
End Stage Kidney Disease (ESRD)
Effect of the Amplifi™ Vein Dilation System on Outflow Vein Dilation and AV Fistula Maturation (AMPLIFI-1)
The AMPLIFI-1 Study is a prospective, multicenter pivotal clinical trial designed to evaluate the safety and effectiveness of the Amplifi™ Vein Dilation System in patients requiring distal arteriovenous fistula (AVF) creation for…
- Trial name
- AMPLIFI-1 (NCT07211035)
- Testing
- The Amplifi System is a temporary extracorporeal blood pump designed to deliver controlled flow through a peripheral vein for 24-72 hours prior to AVF creation., Standard of Care (AVF creation)
- Where
- 2 sites in United States
- Volunteers
- 160 people
- Sponsor
- Amplifi Vascular, Inc.
Hemodialysis Fistula Thrombosis
Evaluation of Heparin Bonded Vascular Graft Versus Standard Graft in Prosthetic Arteriovenous Access for Hemodialysis
The majority of bridge graft fistula with polytetrafluoroethylene (PTFE) for hemodialysis access will develop stenosis at the venous anastomosis and eventually will fail.
- Trial name
- NCT00737620
- Testing
- Prosthetic AV graft implantation
- Where
- Israel
- Volunteers
- 160 people
- Sponsor
- Shaare Zedek Medical Center
Renal Failure
Assessment of the Sympathetic Nervous System Blockade of the Upper Limb After a Brachial Plexus Block in Patients With End Stage Renal Failure
The purpose of this study is to investigate what effect a local anesthetic nerve block of the arm in patients with end stage renal failure has upon blood flow in the skin of the arm.
- Trial name
- NCT01135979
- Where
- United Kingdom
- Sponsor
- University of Nottingham
End Stage Renal Disease
Goal Directed Fluid Administration for Kidney Transplantation
The goal of the proposed study is to evaluate the efficacy of a goal-directed fluid administration algorithm on early graft function in patients undergoing kidney transplantation.
- Trial name
- NCT02192086
- Testing
- goal directed fluid therapy, Control Group
- Volunteers
- 21 people
- Sponsor
- Medical University of South Carolina
End Stage Renal Disease
Accelerated Mortality on Renal Replacement
The purpose of this study is to prospectively identify blood markers that identify chronic hemodialysis patients at risk for early (<90 days) and late (>= 1 year) mortality
- Trial name
- ArMORR (NCT00505180)
- Volunteers
- 10,018 people
- Sponsor
- Massachusetts General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.